Dernières nouvelles pour HUTCHMED (China) (NASDAQ:HCM) Stock

HUTCHMED (China)

HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China) Ltd

HCM ACQUISITION CORP USD CL A ORD SHS

HCM ACQUISITION CORP USD UNITS CONSISTING ONE CL A ORD SH OF $0.0001 PAR VALUE &

HCM ACQUISITION CORP USD RED WTS

HEALTHIER CHOICES MGMT by Healthier Choices Management Corp.

Healthier Choices Management Corp

Holcim Ltd

Direxion Shares ETF Trust Direxion HCM Tactical Enhanced US ETF

HC Wainwright &amp; Co. analyst Mitchell Kapoor maintains Korro Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRRO#NASDAQ">KRRO</a>) with a Buy and lowers the price target from $115 to $100.

News

Price Target

Analyst Ratings

KRRO

HC Wainwright & Co. Maintains Buy on Korro Bio, Lowers Price Target to $100

Fiscal 2025 Outlook
For fiscal year 2025, SharkNinja expects:
<ul>
<li>Net sales to increase 11% to 13% (above the prior expectation of 10% to 12%).</li>
<li>Adjusted Net Income per diluted share between $4.90 and $5.00, reflecting a 12% to 14% increase compared to the prior year (above the prior expectation of between $4.80 and $4.90, reflecting a 10% to 12% increase).</li>
<li>Adjusted EBITDA between $1,090 million and $1,110 million, reflecting a 15% to 17% increase compared to the prior year (above the prior expectation of between $1,070 million and $1,090 million, reflecting a 13% to 15% increase).</li>
<li>A GAAP effective tax rate of approximately 24% to 25%.</li>
<li>Diluted weighted average shares outstanding of approximately 142.5 million.</li>
<li>Capital expenditures of $180 million to $200 million primarily to support investments in new product launches and technology.</li>
</ul>

Guidance

SharkNinja Raises FY2025 Adj EPS Guidance From $4.80-$4.90 To $4.90-$5.00 Vs $4.85 Est; Expects Net Sales To Increase 11% To 13% (Prior 10% To 12%)

Medical Facilities (TSX:<a class="ticker" href="https://www.benzinga.com/stock/DR#TSX">DR</a>) reported quarterly earnings of $0.17 per share which missed the analyst consensus estimate of $0.22 by 22.73 percent. This is a 142.86 percent increase over earnings of $0.07 per share from the same period last year. The company reported quarterly sales of $81.71 million which missed the analyst consensus estimate of $82.80 million by 1.31 percent. This is a 24.52 percent decrease over sales of $108.26 million the same period last year.

Earnings

Earnings Misses

TSX:DR

Medical Facilities Q1 EPS $0.17 Misses $0.22 Estimate, Sales $81.71M Miss $82.80M Estimate

For the second quarter of 2025, we expect:
•Revenue to grow at a mid-twenties percentage rate on a year-over-year basis;
•Gross profit dollars to grow at a high-teens percentage rate on a year-over-year basis;
•Operating expense as a percentage of revenue to be 39% to 40%;
•Stock-based compensation to be $120 million; and
•Free cash flow margin to be in the mid-teens, similar to the first quarter of 2025.

SHOP

Shopify Expects Revenue Growth Mid-20s Percentage Rate On YoY Basis

Supremex (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SXP#TSX">SXP</a>) reported quarterly earnings of $0.09 per share. This is a 35.71 percent decrease over earnings of $0.14 per share from the same period last year. The company reported $70.23 million in sales this quarter. This is a 4.15 percent decrease over sales of $73.27 million the same period last year.

TSX:SXP

Supremex Q1 Adj. EPS $0.09 Down From $0.14 YoY, Sales $70.23M Down From $73.27M YoY

ALGM

Allegro Microsystems Sees Q1 Adj EPS $0.06-$0.10 vs $0.07 Est; Sees Sales $192.000M-$202.000M vs $188.72M Est

Malibu Boats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBUU#NASDAQ">MBUU</a>) sees FY2025 sales of $787.583 million-$804.163 million vs $805.84 million analyst estimate.

MBUU

Malibu Boats Sees FY2025 Sales $787.583M-$804.163M vs $805.84M Est

Appian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPN#NASDAQ">APPN</a>) raises FY2025 Adj EPS guidance from $0.17-$0.22 to $0.18-$0.26 vs $0.18 analyst estimate. Raises FY2025 sales outlook from $680.00 million-$684.00 million to $680.00 million-$688.00 million vs $679.11 million estimate.

APPN

Appian Raises FY2025 Adj EPS Guidance from $0.17-$0.22 to $0.18-$0.26 vs $0.18 Est; Raises FY2025 Sales Guidance from $680.00M-$684.00M to $680.00M-$688.00M vs $679.11M Est

QTTB

Q32 Bio Q1 2025 EPS $(0.90) Up From $(6.33) YoY, Cash And Cash Equivalents Of $65.5M As Of March 31, 2025 Expected To Provide Financial Runway Into 2H 2026

Appian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPN#NASDAQ">APPN</a>) is looking for Q2 Adj EPS of $(0.15)-$(0.11) vs $(0.13) analyst estimate. sees sales of $158.000 million-$162.000 million vs $162.16 million analyst estimate.

Appian Sees Q2 Adj EPS $(0.15)-$(0.11) vs $(0.13) Est; Sees Sales $158.000M-$162.000M vs $162.16M Est

Altice USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATUS#NYSE">ATUS</a>) sees FY2025 sales of $8.600 billion-$8.700 billion vs $8.56 billion analyst estimate.

ATUS

Altice USA Sees FY2025 Sales $8.600B-$8.700B vs $8.56B Est

Mr. Rees continued, "While we are pleased by the performance of our overall business in April, the new global trade environment as well as business and consumer uncertainty, has made it challenging to predict how consumers may respond in the future. Amid this heightened operating backdrop, we are withdrawing our guidance for 2025. We are committed to remaining transparent to our investment community, our consumers, and our customers as we work to chart a winning course."

CROX

Crocs CEO Mr. Rees Said The Company Is Pleased With April's Performance But Is Pulling 2025 Guidance Amid Growing Uncertainty

Dave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) raises FY2025 sales outlook from $415.00 million-$435.00 million to $460.00 million-$475.00 million vs $499.51 million estimate.

DAVE

Dave Raises FY2025 Sales Guidance from $415.00M-$435.00M to $460.00M-$475.00M vs $499.51M Est

Axogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXGN#NASDAQ">AXGN</a>) affirms FY2025 sales outlook from $215.44 million-$219.19 million to $215.44 million-$219.19 million vs $216.90 million estimate.

AXGN

Axogen Affirms FY2025 Sales Guidance of $215.44M-$219.19M vs $216.90M Est

Altice USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATUS#NYSE">ATUS</a>) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.08) by 100 percent. This is a 220 percent decrease over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $2.15 billion which missed the analyst consensus estimate of $2.16 billion by 0.27 percent. This is a 4.40 percent decrease over sales of $2.25 billion the same period last year.

Altice USA Q1 EPS $(0.16) Misses $(0.08) Estimate, Sales $2.15B Miss $2.16B Estimate

Appian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPN#NASDAQ">APPN</a>) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $0.03 by 333.33 percent. This is a 154.17 percent increase over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $166.43 million which beat the analyst consensus estimate of $163.35 million by 1.88 percent. This is a 11.07 percent increase over sales of $149.84 million the same period last year.

Earnings Beats

Appian Q1 Adj. EPS $0.13 Beats $0.03 Estimate, Sales $166.43M Beat $163.35M Estimate

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) will no longer sell the range extender battery pack for its Cybertruck. The range extender would have let the vehicle achieve a range of over 500 miles.
What Happened: Customers took to social media to share details of an email they received from Elon Musk's company titled "Update to your Cybertruck Range Extender Order." Tesla influencer Sawyer Merritt shared a screenshot in a post on the social media platform X on Wednesday.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">BREAKING: Tesla has cancelled the Cybertruck Range Extender. "We are no longer planning to sell the Range Extender for Cybertruck. As a result, we will be refunding your deposit in full" <a href="https://t.co/yb1xOqecX2">pic.twitter.com/yb1xOqecX2</a>
&mdash; Sawyer Merritt (@SawyerMerritt) <a href="https://twitter.com/SawyerMerritt/status/1920253628012470621?ref_src=twsrc%5Etfw">May 7, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
"We are no longer planning to sell the Range Extender for Cybertruck. As a result, we will be refunding your deposit in full." The email from Tesla said. The range extender was originally available for $16,000 as an extra battery pack that would be fitted on the Cybertruck's bed.
Why It Matters: The news comes in as Musk's EV giant is struggling to sell units of the Cybertruck. The company reportedly has over <a href="https://www.benzinga.com/markets/25/05/45216453/tesla-has-over-10000-units-of-unsold-cybertrucks-in-its-us-inventory-amid-poor-sales-report">10,000 units of unsold Cybertrucks</a> in its U.S. inventory.
In a bid to boost sales and appeal to a wider customer base, Tesla also revamped the truck's <a href="https://www.benzinga.com/news/25/04/44967503/cybertruck-gets-a-down-to-earth-redesign-as-tesla-shifts-to-traditional-pickup-marketing-amid-poor-s">marketing language and strategy </a>to position it as a utilitarian, rugged pickup truck.
Interestingly, the company recently offered <a href="https://www.benzinga.com/25/05/45245835/tesla-hands-out-free-1-year-supervised-fsd-trial-to-select-cybertruck-owners">select Cybertruck owners </a>a 1-year-long free trial of Supervised Full Self-Driving, provided that they subscribe to the service before the June 6, 2025, deadline.
Elsewhere, Tesla also launched a <a href="https://www.benzinga.com/markets/equities/25/04/44755221/tesla-unveils-new-cybertruck-long-range-trim-with-a-362-mile-range-and-reduced-features">cheaper, RWD version</a> of the truck, which offered longer range but missed out on some features like smaller wheels, reduced towing capacity and lower ground clearance. The model retails for $62,490 with the federal EV credit and offers 362 miles of range.
Price Action: TSLA is currently $280.80, gaining 1.66% in pre-market trading, according to<a href="https://pro.benzinga.com/dashboard"> Benzinga Pro data</a>.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link</a>.&nbsp;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45244989/lucid-group-q1-2025-earnings-tesla-rival-announces-58-increase-in-deliveries-plans-to-introduce-a-mid-size-platform-in-2026">Tesla-Rival Lucid Announces 58% Increase In Deliveries, Plans To Introduce Mid-Size Platform In 2026</a></li>
</ul>
Photo courtesy: Jonathan Weiss / Shutterstock.com

Tech

TSLA

Elon Musk's Tesla Scraps Popular $16,000 Cybertruck Range Extender As Sales Dwindle In US

Company received approval from European Medicines Agency (EMA) for CLN-978; Phase 1 study in active, difficult-to-treat rheumatoid arthritis to initiate in Q2 2025
CLN-978 expands into Sjögren's disease; Phase 1 study in active, moderate to severe patients to initiate in the U.S. in Q2 2025
Zipalertinib REZILIENT1 results to be shared in oral presentation at 2025 ASCO Annual Meeting

CGEM

Cullinan Therapeutics Receives EMA Approval For CLN-978; Phase 1 Study In Active, Difficult-To-Treat Rheumatoid Arthritis To Initiate In Q2 2025

XERS

Xeris Biopharma Holdings Raises FY2025 Sales Guidance from $255.00M-$275.00M to $260.00M-$275.00M vs $317.63M Est

Apyx Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APYX#NASDAQ">APYX</a>) affirms FY2025 sales outlook from $47.60 million-$49.00 million to $47.60 million-$49.00 million vs $48.03 million estimate.

APYX

Apyx Medical Affirms FY2025 Sales Guidance of $47.60M-$49.00M vs $48.03M Est

Press Releases

HUTCHMED to Announce 2024 Final Results

Management

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

Health Care

HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

HUTCHMED Reports 2024 Full Year Results and Provides Business Updates

General

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025

Intended Retirement of Independent Non-executive Directors and changes of composition of board committees

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

HUTCHMED (China)

Actualités

Dernières nouvelles pour HUTCHMED (China) (NASDAQ:HCM) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL